Bacteriological and serological evidence of brucellosis in Sub-Saharan Africa are reviewed. Strategies for implementation of animal vaccination are discussed. There is a need for simpler and more affordable treatments for human brucellosis. Development of a B. melitensis vaccine to circumvent the drawbacks of Rev 1 is overdue. Performance of serological tests for camel and wildlife brucellosis should be investigated.